GSK has announced headline data from two pivotal phase III trials for bepirovirsen, a chronic hepatitis B treatment that could transform care for a disease affecting approximately 250 million people
All posts tagged in drug development
9Articles
AstraZeneca has recorded its highest quarterly revenue to date, achieving a ten per cent increase and surpassing analyst expectations. The FTSE 100 pharmaceutical group announced total third quarter revenue had
Alzheimers patients can extend cognitive health for years with breakthrough drugs ||| Groundbreaking trial results have revealed that radical new treatments can effectively stall the progression of Alzheimer’s disease for
A groundbreaking development in pharmaceutical research has unveiled gepotidacin as the first new antibiotic treatment for gonorrhoea in three decades, presenting significant market implications for healthcare investors. The innovation addresses
In a groundbreaking announcement at the World Economic Forum in Davos, Sir Demis Hassabis revealed that Isomorphic Labs, the Alphabet-owned drug discovery startup, will commence trials of its first AI-designed
Artificial intelligence is revolutionising pharmaceutical research, offering groundbreaking opportunities for drug discovery whilst potentially saving billions in development costs. Leading pharmaceutical giants GSK and AstraZeneca are at the forefront of
Groundbreaking research indicates that popular weight-loss medications like Ozempic, Wegovy, and Mounjaro might have far-reaching applications beyond obesity treatment, potentially revolutionising the approach to various chronic conditions. Dr Mo Sarhan,
The pharmaceutical industry has witnessed a dramatic decline in deal activity, reaching its lowest point in nearly a decade as major drugmakers pivot away from commercially ready medicines towards early-stage
The National Health Service (NHS) has announced a groundbreaking initiative to tackle the growing threat of antimicrobial resistance (AMR) by partnering with the pharmaceutical industry. The NHS will negotiate fixed-fee
